Minnow Street Minnow Street
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Alignment Healthcare LLC (ALHC)

Healthcare Healthcare Plans
14.90 $
-20.2% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at Alignment Healthcare LLC.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 11 of our scanner strategies — each hit links to the scanner.

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Basics

Market Cap
3.0$B
Shares Outstanding
207Mio.
Float
90.2%
Beta
1.1

Performance

Perf. 1M
46.60%
Perf. 3M
40.00%
Perf. 6M
21.50%
YTD Performance (%)
9.70%
52-Week-High Distance
-4.9%
Perf. 1Y
55.26%
Perf. 3Y
255.10%
Perf. 5Y
-15.41%

Valuation

very high
P/E
142.3
Forward P/E
204.1
PEG
P/B
14.2
P/S
0.7
EV/EBITDA
68.1
Price/FCF
16.1

Profitability

Gross Margin
12.4%
EBIT Margin
1.3%
Net Margin
0.5%
Return on Equity
12.5%
Return on Assets
2.1%

Balance Sheet & Safety

Equity Ratio
16.4%
Debt/Equity
1.6
Altman Z″
3.26
Piotroski
7 out of 9

Growth

Sales Growth Last Quarter
33.30%
EPS Growth Last Quarter
0.00%
Sales Growth (Year)
46.06%
Forward Sales Growth
25.46%
Forward EPS Growth
52.10%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
3
RS Rating
72
EPS Rating
42
Piotroski
7 out of 9
Fundamental Rating
B (72 out of 100)
Altman Z″
3.26

AI Rating

Uses AI

Alignment Healthcare setzt KI laut eigenen SEC-Berichten operativ in der firmeneigenen Technologieplattform AVA ein: Maschinelles Lernen und künstliche Intelligenz prognostizieren Krankenhaus-Einweisungen, Wiedereinweisungsrisiken, Mitglieder-Zufriedenheit und Kündigungsrisiken, um die Versorgung der Medicare-Advantage-Mitglieder zu steuern. KI ist damit ein internes Werkzeug zur Kostensteuerung und Versorgungskoordination, aber keine eigene Umsatzquelle - das Unternehmen verkauft Krankenversicherung, keine KI-Produkte. Die Risikofaktoren nennen den eigenen KI-Einsatz zudem ausdrücklich als operatives, regulatorisches und rechtliches Risiko, was den Befund „nutzt“ (statt „verkauft“ oder „bedroht“) stützt.

View the full file — quotes, sources, reviewed filings
„Our internal care teams and external providers use AVA, our proprietary technology platform, to coordinate high-quality care for members and manage the complexity of the healthcare system."

Unsere internen Versorgungsteams und externen Leistungserbringer nutzen AVA, unsere firmeneigene Technologieplattform, um eine hochwertige Versorgung der Mitglieder zu koordinieren und die Komplexität des Gesundheitssystems zu bewältigen.

10-K · 2026-02-27 · View SEC filing
„It also uses machine learning and artificial intelligence to help predict various scenarios such as hospital admission and re-admission risk, member satisfaction, disenrollment risk and various disease propensity scores and how to best intervene."

Sie [die AVA-Plattform] nutzt zudem maschinelles Lernen und künstliche Intelligenz, um verschiedene Szenarien vorherzusagen - etwa das Risiko von Krankenhaus-Einweisungen und Wiedereinweisungen, die Mitglieder-Zufriedenheit, das Kündigungsrisiko und diverse Krankheits-Wahrscheinlichkeitswerte - sowie um zu bestimmen, wie am besten einzugreifen ist.

10-K · 2026-02-27 · View SEC filing
„Our use of machine learning and artificial intelligence, including within our AVA platform, may introduce operational, regulatory and legal risks that could adversely affect our business, financial condition and results of operations."

Unser Einsatz von maschinellem Lernen und künstlicher Intelligenz, auch innerhalb unserer AVA-Plattform, kann operative, regulatorische und rechtliche Risiken mit sich bringen, die unser Geschäft, unsere Finanzlage und unsere Geschäftsergebnisse beeinträchtigen könnten.

10-K · 2026-02-27 · View SEC filing

Filings Reviewed: 10-Q 2026-04-30 · 10-Q 2025-10-30 · 10-Q 2025-07-30 · 10-Q 2025-05-01 · 10-K 2026-02-27 · 10-K 2025-02-27

Rated on July 10, 2026 · How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 14.90 $
Price Target (average) 24.92 $

The price target sits 67.2% above the current price.

Consensus
Strong Buy

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Sales Per Quarter ($M)
2024: Q4 · 701.2 $M Q4 2025: Q1 · 926.9 $M Q1 2025: Q2 · 1,015.3 $M Q2 2025: Q3 · 993.7 $M Q3 2025: Q4 · 1,012.8 $M Q4 2026: Q1 · 1,235.2 $M Q1 2026: Q2 · 1,335.6 $M Q2
Earnings Per Share Per Quarter ($)
2024: Q4 · -0.16 $ Q4 2025: Q1 · -0.05 $ Q1 2025: Q2 · 0.07 $ Q2 2025: Q3 · 0.02 $ Q3 2025: Q4 · -0.05 $ Q4 2026: Q1 · 0.05 $ Q1 2026: Q2 · 0.17 $ Q2
Net Margin Per Quarter (%)
2024: Q4 · -4.4 % Q4 2025: Q1 · -1.0 % Q1 2025: Q2 · 1.5 % Q2 2025: Q3 · 0.4 % Q3 2025: Q4 · -1.1 % Q4 2026: Q1 · 0.9 % Q1 2026: Q2 · 2.7 % Q2
Operating Cash Flow Per Quarter ($M)
2024: Q4 · -8.7 $M Q4 2025: Q1 · 16.6 $M Q1 2025: Q2 · 29.1 $M Q2 2025: Q3 · 144.6 $M Q3 2025: Q4 · -50.4 $M Q4 2026: Q1 · 128.7 $M Q1 2026: Q2 · -17.3 $M Q2
Free Cash Flow Per Quarter ($M)
2024: Q4 · -18.0 $M Q4 2025: Q1 · 8.4 $M Q1 2025: Q2 · 21.1 $M Q2 2025: Q3 · 160.8 $M Q3 2025: Q4 · -66.6 $M Q4 2026: Q1 · 121.3 $M Q1 2026: Q2 · -27.4 $M Q2
Sales Growth vs. Year-Ago Quarter (%)
2024: Q4 · 50.7 % Q4 2025: Q1 · 47.5 % Q1 2025: Q2 · 49.0 % Q2 2025: Q3 · 43.5 % Q3 2025: Q4 · 44.4 % Q4 2026: Q1 · 33.3 % Q1 2026: Q2 · 31.5 % Q2
EPS Growth vs. Year-Ago Quarter (%)
2026: Q2 · 142.9 % Q2
Price Change in Quarter (%)
2024: Q4 · -4.8 % Q4 2025: Q1 · 65.5 % Q1 2025: Q2 · -24.8 % Q2 2025: Q3 · 24.6 % Q3 2025: Q4 · 13.2 % Q4 2026: Q1 · -10.8 % Q1

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 -0.16 701 50.70 -4.40 -9 -18
2025: Q1 -0.05 927 47.50 -1.00 17 8
2025: Q2 0.07 1,015 49.00 1.50 29 21
2025: Q3 0.02 994 43.50 0.40 145 161
2025: Q4 -0.05 1,013 44.40 -1.10 -50 -67
2026: Q1 0.05 1,235 33.30 0.90 129 121
2026: Q2 0.17 142.90 1,336 31.50 2.70 -17 -27
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

Alignment Healthcare, Inc. betreibt eine verbraucherorientierte Gesundheitsplattform für Senioren in den USA.

CEO Insider Trades (12 Mo.)selling own stock
Employees1,849
HeadquartersOrange, CA
Websitealignmenthealth.com
IPO Date26. Mar 2021

Management

Management
Name Title Birth Year
John E. Kao Founder, Chairman & CEO 1962
Joseph Samuel Konowiecki J.D. Vice Chairman & Executive VP of Corporate Affairs 1954
Dawn Christine Maroney President 1968
James M. Head Chief Financial Officer 1966
Christopher J. Joyce J.D. Chief Legal & Administrative Officer 1964
Hyong J. Kim M.D. Chief Medical Officer 1970
Donald S. Furman M.B.A., M.D. Co-Founder & Chief Clinical Officer 1951
Shane Hochradel Chief Operations Officer
Robert L. Scavo Chief Information Officer 1965
Andreas Wagner Chief Human Resources Officer 1970

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
15. Jul 2026 Maroney Dawn Christine President Sell 177,068 20.83 3,687,990
15. Jul 2026 Maroney Dawn Christine President Other 152,068 9.06 1,377,736
10. Jul 2026 Kao John E Chief Executive Officer Sell 18,356 20.65 378,998
10. Jul 2026 Kao John E Chief Executive Officer Sell 279,644 19.81 5,540,363

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?